{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-24-000003","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.285328+00:00","generated_at":"2026-06-07T01:56:43.060185+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC reports prelim 2023 revenue $946M (+35% YoY); guides 2024 rev $600-850M","bullets":["Unaudited 2023 total revenue $946M (+35% YoY); net product revenue $661M (+23% YoY).","DMD franchise: Translarna $355M, Emflaza $255M; Evrysdi royalty/collab revenue $278M.","2024 revenue guidance $600-850M (decline); GAAP R&D+SG&A $740-835M; non-GAAP $660-755M.","Sepiapterin MAA in EU Q1, NDA in US by Q3; PTC518 HD interim data Q2.","CHMP opinion on Translarna re-examination late Jan 2024; $1B Royalty Pharma deal closed."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-24-000003","json":"https://secwatch.observer/filing/0001070081-24-000003.json","markdown":"https://secwatch.observer/filing/0001070081-24-000003.md","text":"https://secwatch.observer/filing/0001070081-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/tmb-20240108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:56:43.060185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73e7cbd7d49fa9db5c3c4666acc82bfc5cffc2f0","claim":"PTC THERAPEUTICS, INC. reported full year 2024 results: revenue $600 million to $850 million. Guidance initiated.","evidence_excerpt":"PTC anticipates total revenues for the full year 2024 to be between $600 million and $850 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$600 million to $850 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c04e571435ae8fe06eaf66dd7f46e6adc57d1dff","claim":"PTC THERAPEUTICS, INC. reported full year 2023 results: revenue $946 million.","evidence_excerpt":"Total unaudited net revenue for full year 2023 was approximately $946 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000003/0001070081-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$946 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}